A potent and selective inhibitor targeting human and murine 12/15-LOX.

[1]  A. Hallberg,et al.  N-Substituted pyrazole-3-carboxamides as inhibitors of human 15-lipoxygenase. , 2015, Bioorganic & medicinal chemistry letters.

[2]  A. Hallberg,et al.  3-Substituted pyrazoles and 4-substituted triazoles as inhibitors of human 15-lipoxygenase-1. , 2015, Bioorganic & medicinal chemistry letters.

[3]  Petra E. van der Wouden,et al.  Identification of 6-benzyloxysalicylates as a novel class of inhibitors of 15-lipoxygenase-1. , 2015, European journal of medicinal chemistry.

[4]  H. Kuhn,et al.  Mammalian lipoxygenases and their biological relevance. , 2015, Biochimica et biophysica acta.

[5]  A. Shafiee,et al.  Imidazo[2,1-b]thiazole derivatives as new inhibitors of 15-lipoxygenase. , 2014, European journal of medicinal chemistry.

[6]  A. Shafiee,et al.  Synthesis, biological evaluation and docking study of 3-aroyl-1-(4-sulfamoylphenyl)thiourea derivatives as 15-lipoxygenase inhibitors. , 2014, European journal of medicinal chemistry.

[7]  Adam Yasgar,et al.  Potent and Selective Inhibitors of Human Reticulocyte 12/15-Lipoxygenase as Anti-Stroke Therapies , 2014, Journal of medicinal chemistry.

[8]  T. Holman,et al.  Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases. , 2013, Bioorganic & medicinal chemistry.

[9]  K. van Leyen,et al.  Lipoxygenase: an emerging target for stroke therapy. , 2013, CNS & neurological disorders drug targets.

[10]  M. Iranshahi,et al.  Synthesis and SAR studies of mono O-prenylated coumarins as potent 15-lipoxygenase inhibitors. , 2012, European journal of medicinal chemistry.

[11]  J. Haeggström,et al.  Lipoxygenase and leukotriene pathways: biochemistry, biology, and roles in disease. , 2011, Chemical reviews.

[12]  A. Jadhav,et al.  Discovery of potent and selective inhibitors of human reticulocyte 15-lipoxygenase-1. , 2010, Journal of medicinal chemistry.

[13]  O. Werz,et al.  5-Lipoxygenase inhibitors: a review of recent developments and patents , 2010, Expert opinion on therapeutic patents.

[14]  C. Funk,et al.  A cell-based assay for screening lipoxygenase inhibitors. , 2009, Prostaglandins & other lipid mediators.

[15]  Victor A Kenyon,et al.  Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2. , 2007, Bioorganic & medicinal chemistry.

[16]  K. Arai,et al.  Baicalein and 12/15-Lipoxygenase in the Ischemic Brain , 2006, Stroke.

[17]  C. Funk.  Lipoxygenase pathways as mediators of early inflammatory events in atherosclerosis. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[18]  J. Macor,et al.  Tryptamine and homotryptamine-based sulfonamides as potent and selective inhibitors of 15-lipoxygenase. , 2005, Bioorganic & medicinal chemistry letters.

[19]  Victor A Kenyon,et al.  Redox inactivation of human 15-lipoxygenase by marine-derived meroditerpenes and synthetic chromanes: archetypes for a unique class of selective and recyclable inhibitors. , 2004, Journal of the American Chemical Society.

[20]  Tyler A. Johnson,et al.  Exploring sponge-derived terpenoids for their potency and selectivity against 12-human, 15-human, and 15-soybean lipoxygenases. , 2003, Journal of natural products.

[21]  A. Brash.  Lipoxygenases: Occurrence, Functions, Catalysis, and Acquisition of Substrate* , 1999, The Journal of Biological Chemistry.

[22]  Thomas D. Y. Chung,et al.  A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays , 1999, Journal of biomolecular screening.

[23]  P. Maher,et al.  A Role for 12-lipoxygenase in Nerve Cell Death Caused by Glutathione Depletion , 1997, Neuron.

[24]  Joseph P. Broderick,et al.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .

[25]  R. D. Dyer,et al.  5-lipoxygenase inhibitory activity of zileuton. , 1991, The Journal of pharmacology and experimental therapeutics.

[26]  R. McMillan,et al.  Designing therapeutically effective 5-lipoxygenase inhibitors. , 1992, Trends in pharmacological sciences.